myopathies. 18 All patients underwent coronary angiography, and patients with coronary artery disease were excluded. Patients who had clinical or laboratory evidence of diabetes mellitus were also excluded. Of the 47 patients, 12 were classified as New York Heart Association (NYHA) functional class grade III, 30 as Class II and 5 as Class I before the administration of -blocker. Fifteen subjects (mean age 53±15, range 23-74 years) who had no evidence of organic cardiac disease or diabetes mellitus were retrospectively selected as a control group for the measurement of insulin resistance. There were no significant differences in age, gender or body mass index between the DCM group and the control group (Table 1 ). The study protocol was approved by the Human Investigations Committee of the institution and all patients gave informed consent before participating in the study.
Study Protocol
Following admission to hospital, all patients with DCM had baseline biochemical and echocardiographic assess- ments carried out. Treatment with a -blocker was then begun for a period of 6 months, each under the same standard therapy, with 14 patients receiving metoprolol, 13 receiving bevantolol and 20 receiving carvedilol. The initial dosage of metoprolol and bevantolol was 2.5 or 5 mg/day and the initial dosage of carvedilol was 1.25 or 2.5 mg/day. The dose was increased every 5-7 days until a maintenance dose was achieved based on the prior dose being clinically tolerated, heart rate at rest remaining between 50 and 70 beats/min and systolic blood pressure more than 90 mmHg. Mean maintenance doses were 36±10 mg (range 20-60 mg) for metoprolol, 53±32 mg (range 20-150 mg) for bevantolol and 16±6 mg (range 10-30 mg) for carvedilol.
Echocardiographic Study M-mode and 2-dimensional echocardiographic studies were performed with an Aloka SSD 9000 or SSD 5500 imaging system (Tokyo, Japan) with 2.5-or 3.5-MHz transducers. The M-mode echocardiogram was recorded on a strip-chart recorder at a paper speed of 50 or 100 mm/s. The following conventional variables were obtained from the M-mode measurements according to the criteria of the American Society of Echocardiography: 19 left ventricular dimension at end-diastole (LVDd) and end-systole (LVDs), left ventricular volume calculated using Teichholtz's formula, and ejection fraction (EF). Arterial blood pressure was determined in duplicate on the day of the echocardiographic studies using a sphygmomanometer.
Measurement of Insulin Resistance
A blood sample was withdrawn from the antecubital vein on the morning of the investigations after the patient had fasted for 12 h. Fasting blood glucose (FBS) and insulin concentrations were measured and used to determine the Homeostatic Model Assessment (HOMA) index of insulin resistance, calculated using the equation; HOMA = FBS × insulin/22.5. 20 
Measurement of TNF-(TNF-)
Blood samples for TNF-analysis were collected into chilled tubes, immediately centrifuged at 4°C, stored at -80°C and analyzed using an enzyme-linked immunosorbent assay (Immunotech Co, Marseille, France). The average inter-and intra-assay coefficients of variation were <10% for all the assays carried out.
Statistical Analysis
Data were analyzed using StatView (Abacus Concepts, Inc, Berkeley, CA, USA, 1994) and expressed as mean ± SD. The level of significance for comparative analyses was set at p<0.05. Baseline characteristics, except for insulin concentration and HOMA index, were analyzed with an unpaired t test or chi-square test for non-parametrically distributed values. The difference in insulin concentration and the HOMA index between DCM patients and controls was compared using the Mann-Whitney U rank-sum test for unpaired data. Changes in the hemodynamic or echocardiographic variables after -blocker therapy were analyzed using Student's paired t test, and changes in NYHA functional class, HOMA index and TNF-were determined by the Wilcoxon signed rank test. The relationship between HOMA index and hemodynamic or echocardiographic parameters before -blocker treatment was assessed by linear regression. The relationship between changes in insulin resistance and changes in echocardiography parameters or plasma TNF-concentration was assessed by linear regression. All calculations were performed on a personal computer with the statistical package StatView (Abacus Concepts, Inc). A value of p<0.05 was considered significant.
Results

Insulin Resistance and Plasma TNF-Concentration
Insulin resistance at baseline was significantly greater in patients with DCM than in the control subjects ( Table 1 ). The effect of -blocker treatment on this variable in the DCM group is shown in Fig 1; there was a significant improvement in insulin resistance (mean HOMA index 2.73± 3.36 vs 1.58±1.33, p=0.04). The plasma TNF-concentration was also significantly decreased after 6 months of treatment with the -blockers ( Table 2) . Table 2 summarizes the changes in echocardiographic parameters, heart rate and systolic blood pressure from baseline to after -blockade. Although systolic blood pressure remained unchanged, there was a significant decrease in heart rate. As anticipated, both LVDd and LVDs decreased while EF increased.
Echocardiography
Relationship Between Insulin Resistance and Hemodynamic, Echocardiographic Parameters or Plasma TNF-Concentration
There was no the relationship between HOMA index and hemodynamic or echocardiographic parameters beforeblocker treatment. There was also no relationship between the improvement in insulin resistance and changes in the echocardiographic parameters or plasma TNF-concentration.
Discussion
The present study confirms that DCM is associated with insulin resistance and shows that treatment with a -blocker attenuated this change in insulin function.
However, the mechanism of this apparent improvement in insulin sensitivity remains unclear. In patients with hypertension, -blockers reportedly induce insulin resistance, possibly by decreasing the metabolic clearance rate of insulin that in turn results in higher insulin concentrations, impaired glucose disposal and hyperglycemia. 14, 17 It is possible that the decrease in cardiac output during treatment with a -blocker may result in decreased blood flow in skeletal muscles, thereby reducing the availability of glucose to the prime target tissue for glucose disposal. 17 However, Malminiemi et al reported that celiprolol, a vasodilating 1-adrenoreceptor antagonist, improved insulin sensitivity in dyslipidemic hypertensive patients; celiprolol had 2-agonist properties, which can cause vasodilation in muscle tissue. 21 Refsgaard et al recently reported that carvedilol is neutral with regard to its influence on insulin sensitivity in patients with congestive heart failure. 22 Pietila et al reported that insulin sensitivity was favorably affected by exercise training in chronic heart failure, and that celiprolol augmented this effect. 23 The findings of the present study in patients with DCM indicate that the effects of improved cardiac function associated with -blockade, such as enhanced exercise capacity and increase peripheral blood flow, may indirectly lead to an increase in insulin sensitivity. Swan et al reached a similar conclusion in a study of patients with heart failure in which it was shown that insulin resistance was a consequence of reduced peak oxygen consumption rather than a result of abnormal ventricular function or changes in norepinephrine activity. 10 However, in the present study we were unable to demonstrate an association between changes in left ventricular function and improved insulin resistance and therefore further investigations are warranted in order to better understand the etiological role of hemodynamic changes on insulin activity.
Our study results also raise the possibility that reductions in plasma TNF-concentration may be a factor contributing to the increase in insulin sensitivity induced by -blockers in DCM. It is well established that TNF-in combination with norepinephrine has an adverse effect on insulin signaling by inhibiting phosphorylation of the insulin receptor. [24] [25] [26] The finding of the present study, and that of an earlier investigation, 27 that -blocker treatment markedly reduced the TNF-concentration raises the possibility that attenuation of the inhibitory effect of this adipocytokine following -blockade results in improved insulin sensitivity. However, as with the hemodynamic results we were unable to demonstrate a significant relationship between changes in cytokine concentration and insulin resistance and therefore more comprehensive and larger studies are required in order to validate the role of TNF-in these beneficial changes associated with -blockers.
Study Limitations
The study protocol was not randomized and the researchers were not blinded to treatment. However, measurements of cardiac function, insulin resistance and TNF-were performed in a blinded manner with regard to treatment groups and time. Another limitation is the small number of study patients. We are aware that a larger number of subjects would have improved the reliability of our results.
Conclusion
Beta-blocker treatment attenuates insulin resistance in patients with DCM and we would suggest that -blockers may be a beneficial adjunct to the treatment regimen of patients with DCM, especially those individuals with insulin resistance.
